AU2002358682B2 - Pre-formulation for the tabletting of natural mixtures of conjugated estrogens - Google Patents
Pre-formulation for the tabletting of natural mixtures of conjugated estrogens Download PDFInfo
- Publication number
- AU2002358682B2 AU2002358682B2 AU2002358682A AU2002358682A AU2002358682B2 AU 2002358682 B2 AU2002358682 B2 AU 2002358682B2 AU 2002358682 A AU2002358682 A AU 2002358682A AU 2002358682 A AU2002358682 A AU 2002358682A AU 2002358682 B2 AU2002358682 B2 AU 2002358682B2
- Authority
- AU
- Australia
- Prior art keywords
- weight
- preformulation
- pharmaceutical
- support material
- oestrogens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 87
- 229940035811 conjugated estrogen Drugs 0.000 title description 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000284 extract Substances 0.000 claims description 107
- 239000000262 estrogen Substances 0.000 claims description 94
- 229940088597 hormone Drugs 0.000 claims description 86
- 239000005556 hormone Substances 0.000 claims description 86
- 239000000463 material Substances 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 73
- 239000013543 active substance Substances 0.000 claims description 58
- 239000007864 aqueous solution Substances 0.000 claims description 51
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 48
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 48
- 239000002245 particle Substances 0.000 claims description 44
- 239000007787 solid Substances 0.000 claims description 44
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 42
- 241000283073 Equus caballus Species 0.000 claims description 34
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 34
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 34
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 28
- 239000008101 lactose Substances 0.000 claims description 28
- 238000005507 spraying Methods 0.000 claims description 28
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 claims description 22
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 claims description 22
- 210000002700 urine Anatomy 0.000 claims description 22
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 21
- 229960003399 estrone Drugs 0.000 claims description 21
- 238000009826 distribution Methods 0.000 claims description 20
- 239000012141 concentrate Substances 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 15
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 13
- 239000000470 constituent Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000005029 sieve analysis Methods 0.000 claims description 9
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- NLLMJANWPUQQTA-UHFFFAOYSA-N 13-methyl-6,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3=CCC2=C1 NLLMJANWPUQQTA-UHFFFAOYSA-N 0.000 claims 1
- NLLMJANWPUQQTA-UBDQQSCGSA-N 7,8-didehydro-17beta-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4C3=CCC2=C1 NLLMJANWPUQQTA-UBDQQSCGSA-N 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 60
- 239000000243 solution Substances 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 22
- 239000003826 tablet Substances 0.000 description 14
- 229920003084 Avicel® PH-102 Polymers 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 235000019888 Vivapur Nutrition 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000006286 aqueous extract Substances 0.000 description 5
- 239000013563 matrix tablet Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- -1 sulphate salt Chemical class 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000000853 cresyl group Chemical class C1(=CC=C(C=C1)C)* 0.000 description 3
- HVDGDHBAMCBBLR-UHFFFAOYSA-N enterolactone Chemical compound OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 3
- JKKFKPJIXZFSSB-CBZIJGRNSA-M estrone 3-sulfate(1-) Chemical compound [O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-M 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- HVDGDHBAMCBBLR-PBHICJAKSA-N Enterolactone Chemical compound OC1=CC=CC(C[C@H]2[C@@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-PBHICJAKSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01129840.3 | 2001-12-14 | ||
| EP01129840 | 2001-12-14 | ||
| PCT/EP2002/014104 WO2003051337A1 (de) | 2001-12-14 | 2002-12-12 | Präformulierung für die tablettierung von natürlichen gemischen konjugierter oestrogene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002358682A1 AU2002358682A1 (en) | 2003-06-30 |
| AU2002358682B2 true AU2002358682B2 (en) | 2009-03-26 |
Family
ID=8179550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002358682A Ceased AU2002358682B2 (en) | 2001-12-14 | 2002-12-12 | Pre-formulation for the tabletting of natural mixtures of conjugated estrogens |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8273728B2 (enExample) |
| EP (1) | EP1458363B1 (enExample) |
| JP (1) | JP4695838B2 (enExample) |
| CN (2) | CN100502839C (enExample) |
| AR (1) | AR037642A1 (enExample) |
| AU (1) | AU2002358682B2 (enExample) |
| BR (1) | BR0214954A (enExample) |
| CA (1) | CA2470209A1 (enExample) |
| ES (1) | ES2403218T3 (enExample) |
| MX (1) | MXPA04005767A (enExample) |
| PL (1) | PL205544B1 (enExample) |
| TW (1) | TWI332400B (enExample) |
| WO (1) | WO2003051337A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9586335B2 (en) * | 2010-01-27 | 2017-03-07 | Sd3, Llc | Blade guard with dust collection |
| TWI332400B (en) * | 2001-12-14 | 2010-11-01 | Solvay Pharm Gmbh | Preformulation for the tableting of natural mixtures of conjugated estrogens |
| US8349819B2 (en) | 2002-10-09 | 2013-01-08 | Dr. Reddy's Laboratories New York, Inc. | Steroid extraction process from urine sources |
| US6992075B2 (en) * | 2003-04-04 | 2006-01-31 | Barr Laboratories, Inc. | C(14) estrogenic compounds |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US20090232897A1 (en) * | 2008-03-14 | 2009-09-17 | Bijayananda Sahoo | Pharmaceutical compositions comprising conjugated estrogens |
| WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| CA2768452A1 (en) * | 2009-07-16 | 2011-01-20 | Avantor Performance Materials, Inc. | Material and process for incorporation of low dosage active pharmaceutical ingredients and use thereof |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| EP2787987B1 (de) * | 2011-12-08 | 2016-06-01 | Hexal AG | Neue pharmazeutische statin-zusammensetzung |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US20210246928A1 (en) * | 2020-02-11 | 2021-08-12 | Carl Chasse | Fastener having improved wobble control, fastening system including the same, and method of forming the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3487152A (en) * | 1967-02-07 | 1969-12-30 | Hoffmann La Roche | Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances |
| US4154820A (en) | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
| DE3535536A1 (de) * | 1985-10-04 | 1987-04-09 | Lentia Gmbh | Verfahren zum gleichzeitigen trocknen und granulieren von extraktstoffen aus enteiweisstem kaelberblut |
| EP0322020A1 (en) * | 1987-12-22 | 1989-06-28 | Akzo N.V. | Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis |
| ATE264110T1 (de) | 1996-08-30 | 2004-04-15 | Solvay Pharm Gmbh | Prozess zur gewinnung von oestrogenen aus stutenharn |
| DK0923381T3 (da) | 1996-08-30 | 2004-05-10 | Solvay Pharm Gmbh | Fremgangsmåde til fremstilling af östrogener ud fra hoppeurin |
| US6200289B1 (en) | 1998-04-10 | 2001-03-13 | Milestone Scientific, Inc. | Pressure/force computer controlled drug delivery system and the like |
| JP2000156938A (ja) | 1998-11-19 | 2000-06-06 | Hokuto Denko Kk | 電池の充放電試験装置 |
| TWI332400B (en) * | 2001-12-14 | 2010-11-01 | Solvay Pharm Gmbh | Preformulation for the tableting of natural mixtures of conjugated estrogens |
-
2002
- 2002-11-29 TW TW091134752A patent/TWI332400B/zh not_active IP Right Cessation
- 2002-12-04 AR ARP020104698A patent/AR037642A1/es unknown
- 2002-12-12 CA CA002470209A patent/CA2470209A1/en not_active Abandoned
- 2002-12-12 CN CNB2006101684418A patent/CN100502839C/zh not_active Expired - Fee Related
- 2002-12-12 PL PL368730A patent/PL205544B1/pl unknown
- 2002-12-12 MX MXPA04005767A patent/MXPA04005767A/es active IP Right Grant
- 2002-12-12 CN CNB028262077A patent/CN1298313C/zh not_active Expired - Fee Related
- 2002-12-12 WO PCT/EP2002/014104 patent/WO2003051337A1/de not_active Ceased
- 2002-12-12 EP EP02792980A patent/EP1458363B1/de not_active Expired - Lifetime
- 2002-12-12 AU AU2002358682A patent/AU2002358682B2/en not_active Ceased
- 2002-12-12 BR BR0214954-0A patent/BR0214954A/pt not_active IP Right Cessation
- 2002-12-12 ES ES02792980T patent/ES2403218T3/es not_active Expired - Lifetime
- 2002-12-12 JP JP2003552270A patent/JP4695838B2/ja not_active Expired - Fee Related
-
2004
- 2004-06-14 US US10/866,095 patent/US8273728B2/en not_active Expired - Fee Related
-
2012
- 2012-05-30 US US13/483,530 patent/US8329679B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
Also Published As
| Publication number | Publication date |
|---|---|
| PL368730A1 (en) | 2005-04-04 |
| CN100502839C (zh) | 2009-06-24 |
| CN1298313C (zh) | 2007-02-07 |
| TW200408400A (en) | 2004-06-01 |
| CN1607944A (zh) | 2005-04-20 |
| HK1075007A1 (en) | 2005-12-02 |
| CA2470209A1 (en) | 2003-06-26 |
| CN1977862A (zh) | 2007-06-13 |
| ES2403218T3 (es) | 2013-05-16 |
| AU2002358682A1 (en) | 2003-06-30 |
| JP4695838B2 (ja) | 2011-06-08 |
| BR0214954A (pt) | 2004-12-14 |
| JP2005516923A (ja) | 2005-06-09 |
| US20120237666A1 (en) | 2012-09-20 |
| US8329679B2 (en) | 2012-12-11 |
| EP1458363B1 (de) | 2013-01-16 |
| HK1104220A1 (zh) | 2008-01-11 |
| WO2003051337A1 (de) | 2003-06-26 |
| PL205544B1 (pl) | 2010-04-30 |
| MXPA04005767A (es) | 2004-09-10 |
| AR037642A1 (es) | 2004-11-17 |
| US8273728B2 (en) | 2012-09-25 |
| TWI332400B (en) | 2010-11-01 |
| EP1458363A1 (de) | 2004-09-22 |
| US20050009800A1 (en) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002358682B2 (en) | Pre-formulation for the tabletting of natural mixtures of conjugated estrogens | |
| RU2166936C2 (ru) | Способ получения дозировочных единиц путем мокрой грануляции | |
| CA1338553C (en) | Pharmaceutical granulate containing cellulose product | |
| US20090232897A1 (en) | Pharmaceutical compositions comprising conjugated estrogens | |
| KR20080013776A (ko) | 장용성 고체 분산체의 고형 제제 및 그의 제조 방법 | |
| KR100580855B1 (ko) | 안정화된 티볼론 조성물 | |
| AU2002361396B2 (en) | Matrix film tablet for the controlled release of natural mixtures of conjugated oestrogens | |
| JPH05320045A (ja) | 錠剤に直接圧縮可能な医薬粉末組成物を製造するための噴霧乾燥法 | |
| CS261898B2 (en) | Method of homogeneous granulation product making | |
| HK1104220B (en) | Pre-formulation for the tabletting of natural mixtures of conjugated estrogens | |
| HK1075005B (en) | Matrix film tablets for the controlled release of natural mixtures of conjugated estrogen | |
| HK1075007B (en) | Pre-formulation for the tabletting of natural mixtures of conjugated estrogens | |
| HK1074588A1 (zh) | 含菲諾貝特的水成懸浮物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE NAME FROM SOLVAY PHARMACEUTICALS GMBH TO ABBOTT PRODUCTS GMBH . |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |